I 
117TH CONGRESS 
2D SESSION 
H. R. 8440 
To clarify that the Federal Right to Try law applies to schedule I substances 
for which a phase I clinical trial has been completed and to provide 
access for eligible patients to such substances pursuant to the Federal 
Right to Try law. 
IN THE HOUSE OF REPRESENTATIVES 
JULY 20, 2022 
Mr. BLUMENAUER (for himself, Ms. MACE, Ms. DEAN, Mr. BIGGS, and Mr. 
CORREA) introduced the following bill; which was referred to the Com-
mittee on Energy and Commerce, and in addition to the Committee on 
the Judiciary, for a period to be subsequently determined by the Speaker, 
in each case for consideration of such provisions as fall within the juris-
diction of the committee concerned 
A BILL 
To clarify that the Federal Right to Try law applies to 
schedule I substances for which a phase I clinical trial 
has been completed and to provide access for eligible 
patients to such substances pursuant to the Federal 
Right to Try law. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Right to Try Clarifica-
4
tion Act’’. 
5
VerDate Sep 11 2014 
05:13 Jul 23, 2022
Jkt 029200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H8440.IH
H8440
pbinns on DSKJLVW7X2PROD with $$_JOB
2 
•HR 8440 IH
SEC. 2. FINDINGS. 
1
Congress finds as follows: 
2
(1) The Trickett Wendler, Frank Mongiello, 
3
Jordan McLinn, and Matthew Bellina Right to Try 
4
Act of 2017 (Public Law 115–176) was enacted in 
5
2018. 
6
(2) Section 561B of the Federal Food, Drug, 
7
and Cosmetic Act (21 U.S.C. 360bbb–0a), as added 
8
by the Act described in paragraph (1) (referred to 
9
in this section as the ‘‘Federal Right to Try law’’), 
10
does not exclude from the application of such law 
11
schedule I substances for which a phase I clinical 
12
trial has been completed. 
13
(3) Multiple schedule I drugs have progressed 
14
through phase I clinical trials and have been des-
15
ignated by the Food and Drug Administration as 
16
breakthrough therapies under section 506 of the 
17
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
18
356) because of preliminary clinical evidence indi-
19
cating that such drugs demonstrate substantial im-
20
provement over existing therapies, but eligible pa-
21
tients have not been permitted access to these drugs 
22
pursuant to the Federal Right to Try law. 
23
SEC. 3. AMENDMENT TO FEDERAL RIGHT TO TRY LAW. 
24
Section 561B(b) of the Federal Food, Drug, and Cos-
25
metic Act (21 U.S.C. 360bbb–0a(b)) is amended by insert-
26
VerDate Sep 11 2014 
05:13 Jul 23, 2022
Jkt 029200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H8440.IH
H8440
pbinns on DSKJLVW7X2PROD with $$_JOB
3 
•HR 8440 IH
ing ‘‘any provision of the Controlled Substances Act (21 
1
U.S.C. 801 et seq.) that prohibits the unauthorized use, 
2
possession, distribution, dispensation, or transportation of 
3
an eligible investigational drug,’’ before ‘‘and parts’’. 
4
Æ 
VerDate Sep 11 2014 
05:13 Jul 23, 2022
Jkt 029200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6301
E:\BILLS\H8440.IH
H8440
pbinns on DSKJLVW7X2PROD with $$_JOB
